Kate J. Newberry

5.1k citations

61 papers · 1.9k indexed · h-index 25

Molecular Biology top 10%
Genetics top 1%
Hematology top 1%
Rheumatology top 2%
Genetics top 10%

Co-authors: Richard G. Brennan Srđan Verstovšek Hagop M. Kantarjian Jörge E. Cortes John J. Perona Taghi Manshouri Elias Jabbour Lucia Masárová
Topics: Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers)Acute Myeloid Leukemia Research (18 papers)Chronic Myeloid Leukemia Treatments (12 papers)
Cited by: Genetics Hematology Rheumatology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry The Journal of Experimental Medicine
Partner nations: United States France United Kingdom

In The Last Decade

Kate J. Newberry

61 papers receiving 1.9k citations

Peers

Countries citing papers authored by Kate J. Newberry

Since Specialization

Citations

This map shows the geographic impact of Kate J. Newberry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate J. Newberry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate J. Newberry more than expected).

Fields of papers citing papers by Kate J. Newberry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate J. Newberry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate J. Newberry. The network helps show where Kate J. Newberry may publish in the future.

Co-authorship network of co-authors of Kate J. Newberry

This figure shows the co-authorship network connecting the top 25 collaborators of Kate J. Newberry. A scholar is included among the top collaborators of Kate J. Newberry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate J. Newberry. Kate J. Newberry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assays to enhance metabolic phenotyping in the kidney 2025 ·American Journal of Physiology-Renal Physiology ·(unknown),Justin Kern,(unknown),(unknown),Prabhleen Singh,Kate J. Newberry,Brian N. Finck,Leslie S. Gewin	1
2	VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors (1275) 2023 ·Gynecologic Oncology ·Timothy A. Yap,Manish R. Patel,Brian S. Henick,Kathleen N. Moore,Alexandra Léary,(unknown),(unknown),Hui Zhang,Maria Roche,Kate J. Newberry,(unknown),Dejan Juric	1
3	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial 2017 ·The Lancet Haematology ·Lucia Masárová,Keyur P. Patel,Kate J. Newberry,Jörge E. Cortes,Gautam Borthakur,Marina Konopleva,Zeev Estrov,Hagop M. Kantarjian,Srđan Verstovšek	89
4	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis 2017 ·Leukemia Research ·Lucia Masárová,Prithviraj Bose,Naval Daver,Naveen Pemmaraju,Kate J. Newberry,Taghi Manshouri,Jörge E. Cortes,Hagop M. Kantarjian,Srđan Verstovšek	39
5	Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis 2016 ·The Journal of Experimental Medicine ·Srđan Verstovšek,Taghi Manshouri,Darrell Pilling,Carlos E. Bueso‐Ramos,Kate J. Newberry,(unknown),(unknown),Ksenija Božinović,David Harris,Erika L. Spaeth,Sean M. Post,Asha S. Multani,Raajit K. Rampal,Jihae Ahn,Ross L. Levine,Chad J. Creighton,Hagop M. Kantarjian,Zeev Estrov	115
6	An accurate, simple prognostic model consisting of age, JAK2 , CALR , and MPL mutation status for patients with primary myelofibrosis 2016 ·Haematologica ·Uri Rozovski,Srđan Verstovšek,Taghi Manshouri,Vilma Dembitz,Ksenija Božinović,Kate J. Newberry,Ying Zhang,(unknown),Sherry Pierce,Hagop M. Kantarjian,Zeev Estrov	29
7	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis 2016 ·Leukemia Research ·Dai Chihara,Lucia Masárová,Kate J. Newberry,Hoyoung Maeng,Farhad Ravandi,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Jörge E. Cortes,Hagop M. Kantarjian,Srđan Verstovšek	16
8	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase 2015 ·Leukemia Research ·Talha Badar,Hagop M. Kantarjian,Farhad Ravandi,Elias Jabbour,Gautam Borthakur,Jörge E. Cortes,Naveen Pemmaraju,Sherry R. Pierce,Kate J. Newberry,Naval Daver,Srđan Verstovšek	57
9	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis 2015 ·Haematologica ·Naval Daver,Jörge E. Cortes,Kate J. Newberry,(unknown),Lijun Zhou,(unknown),Sherry Pierce,(unknown),Koji Sasaki,Gautam Borthakur,(unknown),(unknown),Hagop Kantarjian,Srđan Verstovšek	53
10	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis 2015 ·Leukemia & lymphoma ·Koji Sasaki,Jason Gotlib,Ruben A. Mesa,Kate J. Newberry,Farhad Ravandi,Jörge E. Cortes,Patrick J. Kelly,Jeffery L. Kutok,Hagop M. Kantarjian,Srđan Verstovšek	47
11	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome 2015 ·Leukemia Research ·Lucia Masárová,Kate J. Newberry,Sherry Pierce,Zeev Estrov,Jörge E. Cortes,Hagop M. Kantarjian,Srđan Verstovšek	13
12	Clinical significance of microcytosis in patients with primary myelofibrosis 2014 ·Leukemia Research ·Paolo Strati,Naveen Pemmaraju,Zeev Estrov,Marylou Cárdenas-Turanzas,Sherry Pierce,Kate J. Newberry,Naval Daver,Jörge E. Cortes,Hagop M. Kantarjian,Srđan Verstovšek	6
13	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia 2014 ·Leukemia Research ·Naval Daver,Aditi Shastri,Tapan M. Kadia,Kate J. Newberry,Naveen Pemmaraju,(unknown),(unknown),Sherry Pierce,Jörge E. Cortes,Hagop M. Kantarjian,Srđan Verstovšek	26
14	In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome 2013 ·Molecular Cancer Therapeutics ·Liang Zhang,Lan V. Pham,Kate J. Newberry,Zhishuo Ou,(unknown),Jianfei Qian,Luhong Sun,Marzenna Blonska,Yun You,Jing Yang,Xin Lin,(unknown),Archito T. Tamayo,J. Jack Lee,R. Ford,Xiurong Zhao,Larry W. Kwak,Qing Yi,Michael Wang	22
15	Promoter Recognition by a Complex of Spx and the C-Terminal Domain of the RNA Polymerase α Subunit 2010 ·PLoS ONE ·Michiko Nakano,(unknown),(unknown),Kate J. Newberry,Richard G. Brennan,Peter Zuber	44
16	Conformational Plasticity of the Coiled-Coil Domain of BmrR Is Required for bmr Operator Binding: The Structure of Unliganded BmrR 2010 ·Journal of Molecular Biology ·Muthiah Kumaraswami,Kate J. Newberry,Richard G. Brennan	18
17	Structures of BmrR-Drug Complexes Reveal a Rigid Multidrug Binding Pocket and Transcription Activation through Tyrosine Expulsion 2008 ·Journal of Biological Chemistry ·Kate J. Newberry,Joy L. Huffman,(unknown),Nora Vázquez‐Laslop,Alex A. Neyfakh,Richard G. Brennan	38
18	Structural Mechanism of Organic Hydroperoxide Induction of the Transcription Regulator OhrR 2007 ·Molecular Cell ·Kate J. Newberry,Mayuree Fuangthong,Warunya Panmanee,Skorn Mongkolsuk,Richard G. Brennan	107
19	Zinc-mediated Amino Acid Discrimination in Cysteinyl-tRNA Synthetase 2003 ·Journal of Molecular Biology ·Chunmei Zhang,Thomas Christian,Kate J. Newberry,John J. Perona,Ya‐Ming Hou	47
20	Crystallization and preliminary diffraction analysis ofEscherichia colicysteinyl-tRNA synthetase 1999 ·Acta Crystallographica Section D Biological Crystallography ·Kate J. Newberry,Jonathan E. Kohn,Ya‐Ming Hou,John J. Perona	6

About Kate J. Newberry

Kate J. Newberry is a scholar working on Genetics, Hematology and Rheumatology, having authored 61 papers that have together received 1.9k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers), Acute Myeloid Leukemia Research (18 papers) and Chronic Myeloid Leukemia Treatments (12 papers). The work is most often cited by research in Genetics (951 citations), Hematology (791 citations) and Rheumatology (375 citations). Kate J. Newberry has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Richard G. Brennan, Srđan Verstovšek, Hagop M. Kantarjian, Jörge E. Cortes, John J. Perona, Taghi Manshouri, Elias Jabbour, Lucia Masárová, Keyur P. Patel and Naval Daver. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact